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16554 | RSC Adv., 2019, 9, 16554–1656substituent D/A at the 1,2,3-
triazole ring on novel terpyridine derivatives:
synthesis and properties†
Dawid Zych, *a Aneta Slodek, a Dżastin Zimny,a Sylwia Golba,b Katarzyna Malarzc
and Anna Mrozek-Wilczkiewiczc
In this study, we newly designed and developed a synthesis route based on the 1,3-dipolar cycloaddition of
the derivatives of 40-(1,2,3-triazol-4-yl)phenyl-2,20:60,200-terpyridine with various (hetero)aryl substituents,
differing in electronic character, on a triazol ring. The obtained compounds were comprehensively
characterized by UV-Vis spectroscopy and electrochemical and thermal studies. Moreover, preliminary
biological tests were conducted. The investigation allowed the selection of materials with the most
promising properties with particular emphasis on the nature of the substituents. In addition, theoretical
studies (DFT and TD-DFT) were performed to verify the comprehensive understanding of experimental
results.1 Introduction
2,20:60,200-Terpyridine (TPY) derivatives functionalized at
different positions have attracted special interest of scientists
due to their interesting photophysical properties.1,2 They have
become frequently used units in material chemistry research
related to organic electronics,3–5 medicine,6,7 catalysis,8 and
optoelectronics,9–12 as evidenced by a number of scientic
studies conducted in this eld. As a continuation of our
previous studies, herein, we decided to combine a terpyridine
motif with (4-substituted)-1,2,3-triazol-1-yl ring at the position 4
of the phenyl group of 40-phenyl-2,20:60,200-terpyridine and check
the inuence of substituents, i.e. (hetero)aryl groups, on the
properties of target molecules (Fig. 1).
Molecules containing the 1,2,3-triazole motif substituted at
various positions have been of signicant interest due to their
biological properties such as antituberculosis,13 antibacterial14
and antioxidative15 activities; moreover, another discovery is
their ability to image cell structures due to their intense and
selective uorescence in the presence of transition metal
compounds16 and detect ions of these metals in trace
amounts.17 The interest of that kind of structure is also strongly
connected with the discovery of the Cu(I)-catalyzed 1,3-dipolartics, Physics and Chemistry, University of
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cycloaddition of azides and terminal alkynes what has further
triggered the possibility of comprehensive research on both the
structure and synthesis of that heterocycles.18 The widely used
Cu(I)-catalyzed method offers many advantages such as exclu-
sive regioselectivity, a wide substrate scope, and mild
reaction.19,20
As abovementioned, we have already presented the prepa-
ration of a series of 40-(1-substituted-2,3-triazol-4-yl)phenyl-
2,20:60,200-terpyridine derivatives and investigation of their
photophysical and thermal properties and antiproliferative
activity.21 We have found that in the case of the (1-substituted)-
2,3-triazol-4-yl ring, the change in the substituents has an
insignicant effect on its photophysical properties, and iden-
tical maxima of absorption and emission and values of lifetime
have been observed; however, the quantum yields are different.
Moreover, biological studies conducted on a panel of cancer
cells showed that the studied compounds exhibited good anti-
cancer activity at the nanomolar level with a good selectivity
index, and the mechanism of action could be described as the
interaction of these compounds with the DNA of cells.Fig. 1 40-Phenyl-2,20:60,200-terpyridine derivatives containing a 1,2,3-
triazole motif.
































































































View Article OnlineIn this study, we present the synthesis routes of 40-(1-
substituted-2,3-triazol-4-yl)phenyl-2,20:60,200-terpyridines along
with the studies of their optical, thermal, electrochemical, and
biological activity, and particular emphasis was placed on the
inuence of the nature of substituents at the 1,2,3-triazol ring
on the properties of these compounds; this allowed us to nd
themost promisingmaterials. The proper understating of a part
of the experimental results was supported by theoretical
calculations (DFT and TD-DFT).Scheme 1 Synthesis of the compounds 1–3. Reagents and conditions:
(a) NaN3, HMPA, room temp., and 72 h; (b) ethynyl-derivative of A,
CuSO4$5H2O, sodium ascorbate, pyridine, EtOH, H2O, room temp.,
and 24 h; and (c) 2-acetylpyridine, KOH, NH3aq, EtOH, room temp., and
24 h.2 Results and discussion
2.1 Synthesis and structural characterization
The structures of the designed 40-phenyl-2,20:60,200-terpyridine
derivatives with the substituents A1–A7 are presented in Fig. 2.
The rst approach to the synthesis of target 40-phenyl-
2,20:60,200-terpyridine derivatives with the 1,2,3-triazolyl ring
substituted by the various aryl and heteroaryl groups A1–A7, as
presented in Scheme 1, started with the substitution of the nitro
group in 4-nitrobenzaldehyde by the azide anion; this resulted
in the production of 1 with a 78% yield;22 in the next step, 1 was
subjected to a 1,3-dipolar cycloaddition reaction that provided
the 1,2,3-triazole ring 2 substituted at the position 1 by a 4-
formylphenyl group and at the position 4 by an aryl or hetero-
aryl group. Subsequently, the obtained product was used as
a substrate in the next stage of synthesis, i.e. the aldol
condensation reaction, resulting in the formation of the target
compounds 3A1–3A7.
However, due to the low yields of individual steps, related
ethynylaryl and heteroaryl losses, problems with the purica-
tion of intermediates, multiple column chromatography
procedures, polarity of products and affinity towards the
stationary phase, it was decided to develop a new synthetic
route for target compounds.
Another synthetic strategy was to minimize substrate losses
by introducing aryl and heteroaryl groups into the structure
only at the last stage of the synthesis. Therefore, attempts have
been made to synthesize 40-(4-azidophenyl)-2,20:60,200-terpyr-
idine 4 by substituting a bromine atom or a nitro group by the
azide substituent, similar to the reactions well known in the
literature;23,24 however, the expected product is not obtained;Fig. 2 Structures of the designed 40-phenyl-2,20:60,200-terpyridine
derivatives with the substituents A1–A7.
This journal is © The Royal Society of Chemistry 2019this can be probably caused by the absence of an electron-
withdrawing group, such as an aldehyde group, in the structure.
Based on the presented results, a new synthetic route was
developed (Scheme 2), in which 4-azidobenzaldehyde 1, previ-
ously obtained as a result of nucleophilic substitution, was used
as the starting substrate, and in the next stage, it was used in the
Kröhnke reaction to obtain 40-(4-azidophenyl)-2,20:60,200-terpyr-
idine. Then, the obtained intermediate was subjected to a 1,3-
dipolar cycloaddition reaction with the corresponding ethynyl
derivatives of the aryls and heteroaryls A1–A7. As a result, the
products 3A1–3A7 with satisfactory yields, i.e. 21–42%, were
obtained, and purication processes, such as column chroma-
tography, were not required. The crude product was puried by
dissolving it in a small amount of CHCl3 and adding excess of
hexane; it was then taken in a centrifuge tube that was then
placed in an ultrasonic bath for 5 min. The obtained precipitate
was ltered through the fritted funnel G3 and washed with
water and diethyl ether. The novel compounds 3A1–3A7 were
fully characterized by the spectroscopic methods 1H and 13C
NMR and mass spectrometry (ESI Fig. S6–S29†).
2.2 Thermal studies
Thermal properties of the presented compounds 3A1–3A7 and 4
were examined by thermogravimetric analysis (TGA) (under
a nitrogen atmosphere at the heating rate of 15 C min1).
Before the measurement, the samples were dried under vacuumScheme 2 Synthesis of the compounds 4 and 3. Reagents and
conditions: (a) 2-acetylpyridine, KOH, NH3aq, EtOH, room temp., and
24 h and (b) ethynyl derivative of A, CuSO4$5H2O, sodium ascorbate,
pyridine, EtOH, H2O, room temp., and 24 h.
RSC Adv., 2019, 9, 16554–16564 | 16555
































































































View Article Online(0.2 mbar and 80 C) for 6 h. The results are shown in Table 1,
and Fig. 3 presents the TGA curves for all compounds. The DTG
and TGA curves for each compound 3A1–3A7 and 4 are sepa-
rately presented in the ESI Fig. S1.†
The target compounds 3A1–3A7 have high thermal stability.
The temperature of decomposition, which corresponds to a 5%
sample weight loss for the presented 2,20:60,200-terpyridine
derivatives, is higher than 315 C and highest for 3A6, which
contains the dibenzothiophenyl substituent; on the other hand,
the substrate, assigned as 4, used for the synthesis of
compounds 3A1–3A7, shows signicantly lower thermal
stability up to 227 C. Moreover, the char residue at 900 C for
all the examined compounds is higher than 25%, characteristic
for molecules containing aromatic rings, which have the
tendency to yield some char residues that are stable under
a nitrogen atmosphere even at very high temperatures. More-
over, the DTG curves (presented in the ESI†) revealed that the
compounds exhibited weight-loss peaks ranging from one to
three.
2.3 Theoretical studies
Quantum mechanical calculations based on density functional
theory and time-dependent density functional theory were
performed to obtain information about the geometry and the
optical properties of the novel terpyridine derivatives 3A1–3A7.
The B3LYP exchange-correlation functional with the 6-31G**
basis set implemented in the Gaussian 09 program was used.25
The B3LYP/6-31G** geometries were optimized in a chloroform
solution in the polarisable continuous model.26 The obtained
results of optimized geometries (stationary state as an energy
minimum was conrmed by the frequency calculations) with
contours of frontier orbitals, contribution of substituents to the
creation of HOMOs and LUMOs, and the values of the energy
gap (DE) are presented in Table 2.
The optimized geometries of 3A1–3A7 show that the 1,2,3-
triazole ring and the substituents A1–A7 are coplanar, whereas
the phenyl ring and 2,20:60,200-terpyridine are twisted. The values
of the energy gaps are in the range of 3.58–4.54 eV, and highest
values are obtained for 3A3 (4.54 eV) and 3A3 (4.35 eV). The
HOMOs are mainly localized on 4-substituted-1,2,3-triazol-4-yl
groups, and the contribution of a substituent is highest forTable 1 Thermal properties of the synthesized derivatives 3A1–3A7
and 4a
TGA
T5% [C] T10% [C] Tmax [C] Char residue at 900 C [%]
3A1 325 358 416 25
3A2 348 388 471 33
3A3 318 343 373 36
3A4 327 353 498 29
3A5 333 372 496 29
3A6 389 421 519 42
3A7 317 346 376, 471 39
4 227 318 216, 372, 527 25
a T5%, T10% – the temperature of 5% and 10% weight loss, Tmax – the
maximum decomposition rate obtained from the DTG thermograms.
16556 | RSC Adv., 2019, 9, 16554–165643A5, which contains a carbazolyl group (84%), and lowest for
3A3 with a pyridyl group (31%). In the case of 3A1 and 3A3, the
highest occupied molecular orbital is also located on the phenyl
ring, which is directly connected to the central pyridine ring of
terpyridine (contribution of the phenyl ring for 3A1 is 12%, and
that for 3A3 is 21%). The distribution of LUMOs is similar in the
case of the compounds 3A1–3A6, where the mentioned frontier
orbitals are localized on the phenyl, 1,2,3-triazol, and central
pyridine ring of terpyridine, and the participation of the side
pyridine rings of terpyridine is slight. The compound 3A7,
which contains electron-donating substituents at the 1,2,3-tri-
azole ring also has the lowest unoccupied molecular orbital
localized on the substituent 2,20-bithiophene (19%), whereas
the participation of the substituents for 3A1–3A6 is slight (1–
3%).2.4 UV-Vis absorption, photoluminescence, and TD-DFT
study
A number of systematic studies have been reported on the
photophysical properties of 2,20:60,200-terpyridine derivatives
with different aromatic peripheral substituents. Although the
presence of a 1,2,3-triazole group in the terpyridine skeleton has
been rarely introduced,21 it can infer an important effect on the
optical properties of the terpyridine derivatives and thus their
application in optoelectronics andmedicine. The photophysical
and electronic properties of 3A1–3A7 in a chloroform solution
were studied by UV-Vis and uorescence (PL) spectroscopy to
investigate the relation between the character of the substituted
triazole unit in 3A1–3A7 and the photophysical behaviour of
these compounds. The photoluminescence data, lifetime and
quantum yields are listed in Table 3.
The compounds 3A1–3A7 have displayed almost identical
absorption maxima centered around 275 nm, which can be
assigned to the p / p* transitions of the conjugated system
(Fig. 4a). In the case of compound 3A7, an additional band
appears at 330 nm, which can be claried by the distribution
of the electron density of LUMO on the 2,20-bithiophene as
well as terpyridine units as compared to the case of other
compounds, where LUMO is mostly centered on theThis journal is © The Royal Society of Chemistry 2019
Table 2 Contours, energies, and contribution to the creation of HOMOs and LUMOs of 3A1–3A7
HOMO Contribution E [eV] LUMO Contribution E [eV] DE [eV]
3A1 6.13 1.78 4.35
3A2 5.68 1.78 3.90
3A3 6.33 1.79 4.54
3A4 5.66 1.79 3.87
3A5 5.35 1.77 3.58
3A6 5.80 1.81 3.99

































































































Table 2 (Contd. )
HOMO Contribution E [eV] LUMO Contribution E [eV] DE [eV]
































































































View Article Onlineterpyridine part; this low energy absorption band can be
ascribed to an intramolecular charge transfer (ICT) transition
originating partly from a strong donor (2,20-bithiophene) to
an acceptor (terpyridine) moiety.
The results of the TD-DFT calculations that have also been
carried out at the B3LYP level of theory with the 6-31G** basis
set are listed for 3A1 and 3A7 in Table 4 (presenting the calcu-
lated wavelengths of the absorption bands, oscillator strengths,
and transitions); moreover, data for 3A2–3A6 are presented in
the ESI Table S1.† Note that an additional absorption band for
3A7 (330 nm) also appeared, as observed via theoretical calcu-
lations, which had the same character as the lowest energy
bands for the compounds 3A1–3A6; however, it was shied to
longer wavelength.
The photoluminescence spectra of 3A1–3A7 presented in
Fig. 4b indicate the inuence of the substituent at the position 4 of
the triazole unit, and the excitation spectra are presented in the ESI
Fig. S2.† The electronic ability of the substituents in 3A1–3A7
robustly changes their emission spectra. The compound 3A1 with
a weak electron-donating phenyl substituent possesses a similar
emission maximum as the compound 3A3 with the electron-
withdrawing pyridine unit. Moreover, electron-donating substitu-
ents in 3A2 and 3A4–3A7 cause a pronounced bathochromic shi
of the emissionmaximum. The range of this shi is dependent on
the electron-donating character and geometry of the substituents.
Introduction of p-pentoxyphenyl, uorene, and dibenzothiophene
units into the triazole ring in 3A2, 3A4 and 3A6, respectively, results
in a red shi of the emission maximum from 3A6 (378 nm)
through 3A4 (392 nm) to 3A2 (396 nm) due to the stronger donor
ability of these groups. Among the reported compounds, 3A5Table 3 Photophysical data for 3A1–3A7 obtained in the chloroform so
lmax [nm] lex [nm] PL lem [nm] F [%]
3A1 278 280 360 7
3A2 274 318 396 20
3A3 276 320 348, 360 21
3A4 275 326 392 26
3A5 276 324 442 41
3A6 274 316 378 13
3A7 277, 330 280, 330 412 29
16558 | RSC Adv., 2019, 9, 16554–16564possesses the longest emission at 442 nm probably owing to the
strong inuence of its substituent on the electron density of
conjugated bonds. In addition, for the compounds 3A2 and 3A4–
3A7, HOMOs aremostly situated on the A groupswith contribution
in the range of 69–84%, whereas the LUMOs are mainly delo-
calized on the terpyridine, phenyl, and triazole parts, indicating
highly separated and red-shied transition bands in the emission
spectrum.
Based on the theoretical calculations, it can also be proved that
the emission of the compounds 3A1–3A7 strongly depends on the
substituents due to the character of transitions that can be assigned
as transfer of electrons from HOMO to LUMO. Only in the case of
3A3, double emission was observed with a mixed character of
transitions, as also observed via the experimental data (Table 5).
The quantum yields of uorescence for 3A1–3A7 are in
the range of 7–41% and differ depending on the type of
substituents. The compounds 3A5 and 3A7 with pronounced
red-shied emission bands display highest quantum yields
(FF ¼ 30–41%). The measured effective lifetime values are
from 0.41 to 4.21 ns. The monoexponential t was evaluated
in the case of the compound 3A2 and 3A4; however, for other
compounds, the biexponential t was attained (Fig. S3 in the
ESI†).2.5 Electrochemical study
Electrochemical properties of the target compounds 3A1–3A7 were
investigated in a 0.1 M Bu4NPF6 solution in chloroform by cyclic
voltammetry (CV) and differential pulse voltammetry (DPV), and
the concentration of the solution was 1.0 mM L1. The obtainedlution
seff [ns] (weight%) c
2 Eg opt [eV]
0.60 [0.24 (74.09), 1.64 (25.91)] 0.906 3.45
0.73 0.972 3.13
2.03 [1.32 (50.87), 2.77 (49.13)] 0.902 3.45
0.63 1.159 3.17
4.21 [0.11 (5.92), 4.47 (94.08)] 0.998 2.81
0.41 [0.28 (72.69), 0.76 (27.31)] 0.991 3.28
0.66 [0.31 (44.80), 0.94 (55.20)] 0.951 3.01
This journal is © The Royal Society of Chemistry 2019
Fig. 4 (a) Absorption and (b) emission spectra obtained in CHCl3 (c ¼
































































































View Article OnlineCV voltammograms for all compounds are presented in Fig. 5. The
DPV and CV voltammograms presented separately for every
compound are shown in the ESI Fig. S4 and S5.†Table 4 Wavelength maxima [nm] of the absorption spectra together wi
TD-DFT method
Calculated wavelengths [nm] (oscillator strengths) Transitions (c
3A1 316.10 (0.64) HOMO / LU
299.24 (0.12) H1 / LUM
275.42 (0.46) H7 / L+1 (
272.52 (0.54) H7 / L+1 (
264.42 (0.13) H1 / L+1 (
254.36 (0.13) H5 / L+1 (
251.34 (0.23) H1 / L+2 (
247.60 (0.16) H8 / LUM
3A7 383.88 (0.74) HOMO / LU
351.08 (0.53) HOMO / L+
301.50 (0.16) H1 / LUM
286.32 (0.52) H2 / LUM
283.89 (0.13) H4 / LUM
272.12 (0.13) H2 / L+1 (
263.94 (0.20) H1 / L+2 (
261.72 (0.14) H2 / L+2 (
This journal is © The Royal Society of Chemistry 2019The global structure of the investigated samples is same with
various side substituents, leading to changes in electron density
and hence ionization capability of the molecules. The lowest
oxidation potential (and further ionization potential) was found
for 3A6, which contained the electron-rich dibenzothiophene
moiety. Similarly, the presence of an easily oxidizable 2,20-
bithiophene unit leads to low oxidation potential of 3A7.
Substitution of a nitrogen atom into carbon in the uorene
moiety leads to an increase in the oxidation potential of 3A4
with the value similar to that of the alkoxyl-substituted phenyl
ring 3A2, and this value increases upon sulfur substitution such
as in the case of 3A6. Derivatives with the phenyl or pyridine
ring undergo oxidation at the highest potentials.
The electrochemical oxidation and reduction onset poten-
tials shall be utilized to calculate the HOMO and LUMO ener-
gies (which correspond to ionization potentials and electron
affinities) of the materials. The IP of the ferrocene couple was
calculated to be equal to 5.1 eV, as shown by Pron et al.27 The
calculated values are presented in Tables 6 and 7. The oxidation
potentials were used to calculate the HOMO energy level.
However, for LUMO calculation, the optically derived Eg value
was used as the potential of the obtained reduction peaks,
which did not match the oxidation potentials typical for a pyri-
dine system.28 Based on the literature data, it was conrmed
that the reduction peak potential belonged to a side product
formed during the study which appeared as visible green
coloration.29 Using the calculated LUMO level, predictive
reduction potentials of the samples were calculated, which
conrmed their position below 2.5 eV, which was below the
applied measurement potential border and could not be
determined.2.6 Biological study
Anticancer activity of the described terpyridine derivatives 3A1–
3A7 was determined on two cancer cell lines: breast (MCF-7)
and pancreatic (PANC-1). In Table 8, we present the IC50
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Table 5 Calculated TD-DFT wavelengths [nm] in the emission spectra and oscillator strengths for the 3A1–3A7 molecules
Calculated wavelengths
[nm] (oscillator strengths) Experimental PL lem [nm]
D
(theoretical  experimental) Transitions
3A1 384 (1.09) 360 24 HOMO / LUMO (98%)
3A2 432 (0.43) 396 36 HOMO / LUMO (99%)
3A3 331 (0.10) 348, 360 17 H1 / LUMO (86%)
374 (1.51) 14 HOMO / LUMO (98%)
3A4 428 (0.73) 388 40 HOMO / LUMO (98%)
3A5 458 (0.32) 438 20 HOMO / LUMO (99%)
3A6 408 (0.64) 378 30 HOMO / LUMO (98%)
































































































View Article Onlinecell population. Moreover, we performed cytotoxicity assay for
healthy cells (NHDF). The obtained IC50 values for MCF-7 and
PANC-1 are comparable. However, we noticed that the MCF-7
line was slightly more resistant to the investigated terpyr-
idines. Themost active derivative proved to be 3A3 on the PANC-
1 cells (IC50 ¼ 0.114 mM) with lowest lipophilicity. Moreover, TI
was calculated as a ratio of the IC50 normal cells to the IC50
cancer cells. We could nd a correlation between the anticancer
activity and log P. The less active compound 3A5 has highest
log P value. Moreover, the 3A3 derivative exhibited best TI,Fig. 5 Cyclic voltammetry (CV): (a) oxidation, (b) reduction of 3A1–
3A7 (scan rate 0.100 V s1, electrolyte 0.1 M Bu4NPF6 in the CHCl3
solution).
16560 | RSC Adv., 2019, 9, 16554–16564which was equal to 219.3. Overall, three (3A1, 3A2, 3A3) of the
tested compounds possess IC50 values below 1 mM, with high TI,
which makes them an interesting target for further research.
3 Experimental
3.1 Materials
All chemicals were commercially available and used without
purication. Solvents were distilled and purged with nitrogen
before use. All reactions were carried out under an argon
atmosphere.
3.2 4-(4-Azidophenyl)-2,20:60,200-terpyridine (4)
4-Azidobenzaldehyde (5.40 mmol, 0.80 g), 2-acetylpyridine
(10.80 mmol, 1.22 mL) and 50 mL ethanol were placed in
a 150 mL conical ask and mixed for 5 minutes. Then, KOH
(14.86 mmol, 0.84 g) and 25 mL concentrated solution of
ammonia were added. The resulting solution was stirred at
room temperature for 24 hours. The obtained precipitate was
ltered through the fritted funnel G3 and washed with water,
ethanol and diethyl ether; this resulted in the formation of the
product as a yellowish crystalline solid (0.99 g, 52%).
1H NMR (400 MHz, CDCl3) d 8.73–8.70 (m, 2H), 8.68 (d, J ¼
4.5 Hz, 2H), 8.67–8.63 (m, 2H), 7.91–7.82 (m, 3H), 7.78–7.74 (m,
1H), 7.33 (tdd, J ¼ 7.8, 4.8, 1.1 Hz, 2H), 7.16–7.11 (m, 1H), 6.80–
6.75 (m, 1H).
13C NMR (101 MHz, CDCl3) d 156.66, 156.26, 156.13, 155.84,
150.08, 149.24, 149.17, 147.70, 141.02, 137.00, 136.90, 135.23,
128.85, 128.48, 124.00, 123.76, 121.49, 119.64, 118.54, 117.88,
115.33.
HRMS (ESI): m/z calcd for C21H15N6: 351.1358 [MH
+]; found
351.1352.
3.3 1,3-Dipolar cycloaddition for the synthesis of 3A1–3A7
General procedure. In a 50 mL round-bottomed ask, 40-(4-
azidophenyl)-2,20:60,200-terpyridine (0.063 g, 0.18 mmol), ethanol
(7 mL) and water (3 mL) were placed. The mixture was saturated
with argon for 15 minutes and then appropriate amount of
ethynyl aryl (0.22 mmol) (in the case of ethynyl derivatives
protected by trimethylsilyl, the silyl group was removed in situ
using KF (0.048 g, 0.22 mmol)), sodium ascorbate (0.044 g, 0.22
mmol), CuSO4$5H2O (0.055 g, 0.22 mmol), and pyridine (0.15
mL) were added. The mixture was stirred at room temperature
for 48 h. Then, chloroform (20 mL) and a 5% solution ofThis journal is © The Royal Society of Chemistry 2019









3A1 1.02 0.93 6.03 1.81 2.72 2.38 3.65
3A2 0.63 0.51 5.61 1.76 3.31 1.79 3.82
3A3 1.32 1.14 6.24 1.65 2.68 2.42 3.82
3A4 0.70 0.50 5.60 1.69 3.04 2.06 3.54
3A5 0.85 0.69 5.79 1.80 3.13 1.97 3.82
3A6 0.77 0.21 5.31 1.88 3.23 1.87 3.44
3A7 0.83 0.30 5.40 1.98 2.96 2.14 3.26
a E*redðCVÞ – observed reduction peak; E
red
































































































View Article Onlineammonia (15 mL) were added, and the mixture was stirred for
additional time. The mixture was extracted with water (50 mL)
and CHCl3 (2  50 mL). The combined organic layers were
evaporated, and the crude product was dissolved in a small
amount of CHCl3; then, excess of hexane was added, and the
mixture was placed in a centrifuge tube that was then placed in
an ultrasonic bath for 5 min. The obtained precipitate was
ltered through the fritted funnel G3 and washed with water
and diethyl ether.
3A1 (34 mg, 42%) as a brown solid. 1H NMR (400 MHz,
CDCl3) d 8.79 (s, 2H), 8.77–8.73 (m, 2H), 8.70 (d, J ¼ 8.0 Hz, 2H),
8.29 (s, 1H), 8.12–8.07 (m, 2H), 7.97 (dd, J ¼ 11.7, 4.8 Hz, 4H),
7.91 (td, J¼ 7.7, 1.8 Hz, 2H), 7.49 (dd, J¼ 10.3, 4.7 Hz, 2H), 7.42–
7.35 (m, 3H).
13C NMR (101 MHz, CDCl3) d 156.38, 156.17, 149.35, 148.86,
148.78, 139.16, 137.59, 137.12, 130.33, 129.11, 128.93, 128.68,
126.10, 124.18, 121.58, 120.89, 118.86, 117.57.
HRMS (ESI): m/z calcd for C29H21N6: 453.1828 [MH
+]; found
453.1814.
3A2 (39 mg, 40%) as a beige solid. 1H NMR (400MHz, CDCl3)
d 8.79 (s, J ¼ 2.1 Hz, 2H), 8.75 (ddd, J ¼ 4.8, 1.8, 0.8 Hz, 2H),
8.72–8.70 (m, 1H), 8.70–8.68 (m, 1H), 8.19 (s, 1H), 8.10 (t, J ¼
2.2 Hz, 1H), 8.09–8.07 (m, 1H), 7.99–7.94 (m, 2H), 7.91 (td, J ¼
7.7, 1.8 Hz, 2H), 7.88–7.84 (m, 2H), 7.38 (ddd, J ¼ 7.6, 4.7,
1.2 Hz, 2H), 7.03–6.98 (m, 2H), 4.02 (t, J¼ 6.6 Hz, 2H), 1.87–1.77
(m, 2H), 1.52–1.36 (m, 4H), 0.95 (t, J ¼ 7.2 Hz, 3H).
13C NMR (101 MHz, CDCl3) d 159.67, 156.38, 156.19, 149.35,
148.91, 148.74, 139.03, 137.68, 137.13, 128.91, 127.38, 124.17,
122.78, 121.59, 120.83, 118.87, 116.68, 115.10, 68.29, 29.13,




3A1 1.31 0.91 6.01
3A2 0.52 0.49 5.59
3A3 1.17 1.12 6.22
3A4 0.62 0.48 5.58
3A5 0.69 0.69 5.79
3A6 0.53 0.18 5.28
3A7 0.74 0.27 5.37
a E*redðDPVÞ – observed reduction peak; E
red
onset(DPV) ¼ 5.1  ELUMO; LUMO ¼
This journal is © The Royal Society of Chemistry 2019HRMS (ESI): m/z calcd for C34H31N6O: 539.2559 [MH
+];
found 539.2558.
3A3 (28 mg, 34%) as a brown solid. 1H NMR (400 MHz,
CDCl3) d 8.79 (s, 2H), 8.75 (dd, J¼ 5.0, 2.0 Hz, 2H), 8.71–8.68 (m,
3H), 8.66–8.63 (m, 1H), 8.29 (d, J ¼ 7.9 Hz, 1H), 8.12 (d, J ¼
2.1 Hz, 1H), 8.10 (t, J ¼ 2.4 Hz, 1H), 8.01 (q, J ¼ 2.6 Hz, 1H), 7.98
(dd, J ¼ 5.2, 2.5 Hz, 1H), 7.90 (td, J ¼ 7.7, 1.9 Hz, 2H), 7.84 (td, J
¼ 7.8, 1.9 Hz, 1H), 7.38 (ddd, J ¼ 7.7, 4.7, 1.1 Hz, 2H), 7.29 (ddd,
J ¼ 7.7, 5.0, 1.2 Hz, 1H).
13C NMR (101 MHz, CDCl3) d 156.39, 156.17, 150.07, 149.71,
149.35, 148.81, 139.28, 137.52, 137.20, 137.11, 128.98, 124.16,
123.33, 121.56, 120.84, 120.69, 120.01, 118.87.
HRMS (ESI): m/z calcd for C28H20N7: 454.1780 [MH
+]; found
454.1769.
3A4 (21 mg, 21%) as a brown solid. 1H NMR (400 MHz,
CDCl3) d 8.78 (s, 2H), 8.75 (d, J ¼ 4.0 Hz, 2H), 8.69 (d, J ¼
7.9 Hz, 2H), 8.32 (s, 1H), 8.11–8.05 (m, 3H), 7.97 (d, J¼ 8.5 Hz,
2H), 7.93–7.85 (m, 3H), 7.80 (d, J ¼ 7.8 Hz, 1H), 7.76 (dd, J ¼
5.8, 2.4 Hz, 1H), 7.47 (dd, J ¼ 5.7, 2.5 Hz, 1H), 7.40–7.32 (m,
4H), 1.57 (s, 6H).
13C NMR (101 MHz, CDCl3) d 156.34, 156.14, 154.57,
154.09, 149.32, 149.17, 148.80, 139.80, 139.05, 138.85, 137.58,
137.10, 129.17, 128.88, 127.65, 127.21, 125.06, 124.16, 122.81,
121.56, 120.83, 120.59, 120.39, 120.28, 118.81, 117.44, 47.19,
27.30.
HRMS (ESI): m/z calcd for C38H29N6: 569.2454 [MH
+]; found
569.2444.
3A5 (27 mg, 23%) as a brown solid. 1H NMR (400 MHz,
CDCl3) d 8.79 (s, 2H), 8.76 (d, J ¼ 4.0 Hz, 2H), 8.70 (d, J ¼




onset(DPV) LUMO [eV] Eg opt [eV]
— 2.74 2.36 3.65
1.52 3.33 1.77 3.82
1.48 2.70 2.40 3.82
1.52 3.06 2.04 3.54
1.49 3.13 1.97 3.82
1.65 3.26 1.84 3.44
1.61 2.99 2.11 3.26
Eg opt + HOMO.
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Table 8 Cytotoxicity of the 3A1–3A7 derivatives expressed as IC50 values. The therapeutic index (TI) calculated in ACD/ChemSketch log P
IC50 for MCF-7 [mM] IC50 for PANC-1 [mM] IC50 for NHDF [mM] TI for MCF-7 TI for PANC-1 log P
3A1 0.48  0.18 0.29  0.04 >25 >52.41 >87.11 5.91  0.64
3A2 0.87  0.07 0.37  0.08 >25 >28.70 >66.84 7.85  0.64
3A3 0.41  0.03 0.11  0.02 >25 >61.43 >219.30 4.56  0.64
3A4 1.07  0.11 1.87  0.48 >25 >23.30 >13.40 8.88  0.66
3A5 9.96  0.24 3.59  0.78 >25 >2.51 >6.97 11.40  0.69
3A6 1.73  0.12 0.78  0.19 >25 >14.49 >31.89 8.07  0.64
































































































View Article Online8.5 Hz, 2H), 8.03 (dd, J ¼ 6.3, 5.1 Hz, 1H), 7.99 (d, J ¼ 8.5 Hz,
2H), 7.90 (td, J ¼ 7.8, 1.7 Hz, 2H), 7.49 (t, J ¼ 7.8 Hz, 2H), 7.43
(d, J ¼ 8.1 Hz, 1H), 7.41–7.36 (m, 2H), 7.28 (d, J ¼ 7.5 Hz, 1H),
4.32 (t, J ¼ 7.2 Hz, 2H), 1.94–1.85 (m, 2H), 1.45–1.30 (m, 4H),
1.27 (dd, J ¼ 16.7, 5.0 Hz, 6H), 0.87 (t, J ¼ 6.7 Hz, 3H).
13C NMR (126 MHz, DMSO) d 164.99, 157.27, 155.51, 154.46,
149.03, 148.23, 142.42, 137.84, 137.55, 136.13, 136.06, 133.72,
130.93, 129.35, 128.56, 128.36, 125.64, 125.59, 124.60, 124.30,
121.18, 120.63, 118.92, 118.18, 67.13, 38.21, 29.85, 28.29, 23.36,
22.25, 13.73, 10.79.
HRMS (ESI): m/z calcd for C43H40N7: 654.3345 [MH
+]; found
654.3338.
3A6 (27 mg, 27%) as a beige solid. 1H NMR (400 MHz,
CDCl3) d 8.80 (s, 2H), 8.76 (d, J ¼ 3.9 Hz, 2H), 8.70 (d, J ¼
8.0 Hz, 2H), 8.39 (s, 1H), 8.30 (dd, J ¼ 5.5, 3.3 Hz, 1H), 8.11 (d,
J ¼ 8.6 Hz, 2H), 8.03–7.97 (m, 3H), 7.96 (s, 1H), 7.94–7.92 (m,
1H), 7.91 (d, J¼ 1.7 Hz, 1H), 7.89 (d, J ¼ 1.8 Hz, 1H), 7.88–7.86
(m, 1H), 7.53–7.47 (m, 2H), 7.40–7.36 (m, 2H).
13C NMR (101 MHz, CDCl3) d 156.38, 156.16, 149.34, 148.82,
148.79, 140.04, 139.73, 139.19, 137.57, 137.13, 136.37, 135.56,
128.95, 127.21, 126.82, 124.76, 124.70, 124.18, 123.41, 123.05,
122.08, 121.58, 120.88, 119.06, 118.85, 117.58.
HRMS (ESI): m/z calcd for C35H23N6S: 559.1705 [MH
+]; found
559.1699.
3A7 (31 mg, 32%) as a brown solid. 1H NMR (400 MHz,
CDCl3) d 8.79 (s, 2H), 8.75 (d, J ¼ 4.0 Hz, 2H), 8.70 (d, J ¼
8.0 Hz, 2H), 8.19 (s, 1H), 8.10 (d, J ¼ 8.6 Hz, 2H), 7.95 (d, J ¼
8.6 Hz, 2H), 7.91 (td, J ¼ 7.8, 1.7 Hz, 2H), 7.42 (d, J ¼ 3.7 Hz,
1H), 7.38 (dd, J ¼ 6.5, 4.9 Hz, 2H), 7.25–7.23 (m, 2H), 7.19 (d, J
¼ 3.7 Hz, 1H), 7.05 (dd, J ¼ 5.0, 3.7 Hz, 1H).
13C NMR (101 MHz, DMSO) d 155.76, 154.82, 149.09, 142.29,
142.10, 137.68, 137.24, 136.91, 136.07, 135.97, 130.88, 128.36,
128.19, 125.48, 124.47, 124.34, 124.30, 124.17, 120.85, 120.62,
118.83.
HRMS (ESI): m/z calcd for C31H20N6S2: 541.1269 [MH
+];
found 541.1261.3.4 Measurements
NMR spectra were obtained in deuterated chloroform using
Bruker Avance 400 MHz (1H and 13C NMR).
High-resolution mass spectrometry (HRMS) measure-
ments were conducted using Mass Spectrometer QTOF
(Impact HD, Bruker).16562 | RSC Adv., 2019, 9, 16554–16564Thermogravimetric analysis (TGA) was carried out using
Pyris 1 TGA PerkinElmer.
UV/Vis spectra were obtained using the PerkinElmer
Lambda Bio 40 UV/Vis spectrophotometer at room tempera-
ture with a conventional 1.0 cm quartz cell.
The emission and excitation spectra were obtained using
a spectrophotometer (Hitachi F-7000). The quantum yields of
uorescence were determined by the absolute method at
room temperature using an integrating sphere with solvent
as a blank (FLS980 spectrophotometer). The time-resolved
measurement was conducted in optically diluted solutions
at room temperature using the time-correlated single photon
counting methods via the FLS980 spectrophotometer. The
excitation wavelengths were obtained using the picosecond
pulsed diode EPLED–275 nm and 320 nm with 50 ns pulse
period as light sources. PMT (Hamamatsu, R928P) in cooled
housing was used as a detector. The system was leveled at
emission wavelengths. In addition, for the analysis of uo-
rescence decay, an instrument response function was ob-
tained. The IRF contains information about the time
response of the overall optical and electronic system. The IRF
was designated using the LUDOX solution as a standard at
275 and 320 nm.
Electrochemical measurements were conducted using the
PARSTAT 2273 potentiostat – galvanostat. The sample was
dissolved in a chloroform solution with tetrabutylammo-
nium hexauorophosphate Bu4NPF6 (Sigma Aldrich, 99%).
All solutions were freshly prepared and purged with argon
bubbling for 30 minutes. The measurements were conducted
in a three-electrode cell with a 2.0 mL volume of the sample
solution.3.5 Cell culture
The human breast carcinoma (MCF-7) cells were obtained from
ATCC, human Caucasian pancreas (PANC-1) cells were obtained
from ECACC, and the normal human broblasts (NHDF) were
obtained from PromoCell. Cells were grown as monolayer cultures
in Dulbecco's modied Eagle's medium with the antibiotic
gentamicin (200 mL/100 mL medium) in 75 cm2 asks (Nunc).
DMEMs for MCF-7 and PANC-1 were supplemented with 12%
heat-inactivated fetal bovine serum (Sigma) and for NHDF with
15% non-inactivated fetal bovine serum (Sigma). Cells were
cultured under standard conditions at 37 C under a humidied
































































































View Article Online3.6 Cytotoxicity studies
The cells were seeded in 96-well plates (Nunc) at the density
of 5000 cells/well (MCF-7 and PANC-1) and 4000 cells/well
(NHDF) and incubated at 37 C for 24 h. The assay was per-
formed following a 72 h incubation with varying concentra-
tions of the compounds that were being tested. Then, 20 mL of
CellTiter 96®AQueous One Solution-MTS (Promega) was
added to each well (with 100 mL DMEM without phenol red)
followed by incubation for further 1 h at 37 C. The optical
densities of the samples were analyzed at 490 nm using
a multi-plate reader (Synergy 4, Bio Tek). The results were
expressed as a percentage of the control and calculated as the
inhibitory concentration (IC50) values (using GraphPad Prism
7). Each individual compound was tested in triplicate in
a single experiment with each experiment being repeated
three or four times.4 Conclusions
Herein, we presented a synthesis method and comprehensive
characterization of the derivatives 3A1–3A7 of 40-(1,2,3-tri-
azol-4-yl)phenyl-2,20:60,200-terpyridine with various (hetero)
aryl substituents. All compounds were obtained by Cu(I)-
catalysed 1,3-dipolar cycloaddition reactions with yields
between 21 and 42%. The target compounds have high
thermal stability with a temperature of 5% sample weight
loss above 315 C. The compounds 3A1–3A7 have displayed
almost identical absorption maxima (274–278 nm) with an
exception for 3A7 that exhibits an additional band at 330 nm.
All the obtained compounds exhibit uorescence in the range
of 360–442 nm with quantum yields in the range of 7–41%
and effective lifetime values in the range from 0.41 to 4.21 ns.
From the electrochemical point of view, 3A6 with the diben-
zothiophene substituent has lowest oxidation potential,
similar to 3A7 that contains the 2,20-bithiophene unit.
Derivatives with the phenyl or pyridine ring undergo oxida-
tion at highest potentials. The observed differences are in
agreement with the results of the theoretical calculations,
which show disparities of contribution in the creation of
particular orbitals. Moreover, the preliminary tests of the
anticancer activity of the described terpyridine derivatives
3A1–3A7 conducted on two cancer cell lines, i.e. breast (MCF-
7) and pancreatic (PANC-1), show that the group of studied
compounds also has medicinal value, with comparable IC50
values. The most active derivative proved to be 3A3 on the
PANC-1 cells (IC50 ¼ 0.114 mM) with lowest lipophilicity. The
results showed that the examined compounds exhibited
interesting optical as well as biological properties. Thus, this
can indicate their application as potential materials in
organic electronics as well as medicine, and this will be the
subject of our future investigations.Conflicts of interest
There are no conicts to declare.This journal is © The Royal Society of Chemistry 2019Acknowledgements
This work was supported by the Ministry of Science and
Higher Education, Poland (Diamentowy Grant number 0215/
DIA/2015/44 (D. Z.)) and the National Science Centre of
Poland Projects: ETIUDA 6 2018/28/T/ST5/00005 (D. Z.);
PRELUDIUM 12 2016/23/N/NZ7/00351 (K. M.). Calculations
have been carried out using resources provided by Wroclaw
Centre for Networking and Supercomputing (http://wcss.pl),
grant no. 18.Notes and references
1 A. Wild, A. Winter, F. Schlütter and U. S. Schubert, Chem. Soc.
Rev., 2011, 40, 1459–1511.
2 C.-F. Zhang, H.-X. Huang, B. Liu, M. Chen and D.-J. Qian, J.
Lumin., 2008, 128, 469–475.
3 D. Saccone, C. Magistris, N. Barbero, P. Quagliotto, C. Barolo
and G. Viscardi, Materials, 2016, 9, 137.
4 D. Zych, A. Slodek, M. Matussek, M. Filapek, G. Szafraniec-
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Ö. Farkas, J. Foresman, J. Ortiz, J. Cioslowski and D. Fox,
Gaussian 09, Revis. B.01, Gaussian, Inc., Wallingford CT.
26 J. Tomasi, B. Mennucci and R. Cammi, Chem. Rev., 2005,
105, 2999–3094.
27 P. Bujak, I. Kulszewicz-Bajer, M. Zagorska, V. Maurel,
I. Wielgus and A. Pron, Chem. Soc. Rev., 2013, 42, 8895.
28 N. Elgrishi, M. B. Chambers, V. Artero and M. Fontecave,
Phys. Chem. Chem. Phys., 2014, 16, 13635–13644.
29 L. Persaud and G. Barbiero, Can. J. Chem., 1991, 69, 315–321.This journal is © The Royal Society of Chemistry 2019
